Date of report: 06 Feb 2020
Reported case interaction between
Raltegravir and Rifampin
Raltegravir and Rifampin
Drugs suspected to be involved in the DDI
Drug A
Raltegravir
(Victim)
Daily Dose
800
(mg)
Dose adjustment performed
No
Administration Route
Oral
Start date
Dec. 9, 2018
End date
Ongoing
Drug B
Rifampin
(Perpetrator)
Daily Dose
750
(mg)
Dose adjustment performed
No
Administration Route
Oral
Start date
April 9, 2019
End date
Dec. 15, 2019
Complete list of drugs taken by the patient
Antiretroviral treatment
Raltegravir
Emtricitabine/Tenofovir-DF
Complete list of all comedications taken by the patient, included that involved in the DDI
Rifampin, isoniazid, pyrazinamide, ethambutol, pyridoxine, trimethoprim-sulfamethoxazole
Clinical case description
Gender
Male
Age
38
eGFR (mL/min)
>60
Liver function impairment
No
Description
38-year-old male diagnosed with HIV infection in December 2018 (CD4 count of 136 cells/mm3). After 4 months of initiating treatment with RAL + FTC/TDF, he presented lymph node tuberculosis. Treatment was started with isoniazid/rifampicin/pyrazinamide and ethambutol. The patient had a good clinical response and ART maintained effectiveness despite maintaining the standard dose of raltegravir (400 mg bid).
Outcome
No unwanted outcome
Editorial Comment
The recommended dose of raltegravir should be 800 mg twice daily.
Coadministration of rifampicin and raltegravir decreases raltegravir concentrations (AUC by 40%, Cmax by 38% and Cmin by 61%). An interaction study has shown that, when compared to a standard dose of raltegravir (400 mg twice daily), 800 mg twice daily decreased raltegravir trough concentrations by 53%, but increased AUC and Cmax by 27% and 62%, respectively and thus did not overcome the effect of rifampicin on though concentrations.